V1RE10 inhibitors constitute a varied group of compounds that attenuate the protein's activity through interference with specific signaling pathways and biological processes. Inhibitors like Wortmannin and LY294002 exert their effects by targeting the phosphoinositide 3-kinases (PI3K), a pivotal component of the PI3K/AKT pathway, which is essential for numerous cellular functions. By inhibiting PI3K, these compounds indirectly lead to diminished AKT phosphorylation and activity, resulting in lowered functional activity of V1RE10 due to reduced downstream signaling. Rapamycin, another potent V1RE10 inhibitor, acts by specifically binding to the mTOR complex, thereby inhibiting mTOR activity. This inhibition is crucial since mTOR is a central regulator of cell growth and metabolism, and its suppression impacts the protein synthesis and cell cycle progression that may be necessary for V1RE10 signaling. Consequently, the activity of V1RE10 is decreased as the mTOR pathway is a potential contributor to its functionality.
Furthermore, compounds like PD98059, U0126, and SL327 disrupt the MAPK/ERK pathway by inhibiting MEK, which is upstream of ERK activation. This action leads to decreased ERK phosphorylation and activity, a potential requirement for V1RE10's full activation. Inhibitors such as SB203580 and SP600125 target the p38 and JNK MAPKs, respectively, which are involved in cellular responses to stress and cytokines. Inhibition of these kinases can thereby lead to the suppression of V1RE10 activity if it is associated with these stress response pathways. Other inhibitors such as PP2 and AG490 target Src family kinases and JAK2 tyrosine kinases, respectively, influencing the activation of downstream targets and transcriptional events that could be integral to V1RE10's activity. Bafilomycin A1 and Go6983 are also critical in the regulation of V1RE10, with the former disrupting endosomal acidification and the latter modulating protein kinase C (PKC) activity, both of which can have subsequent effects on the functional state of V1RE10.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K). V1RE10 activity is decreased by limiting PI3K-dependent signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A chemical inhibitor of PI3Ks, leading to reduced AKT activation and subsequent downstream signaling affecting V1RE10 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which prevents the activation of downstream targets that may be critical for V1RE10 signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which consequently disrupts the ERK pathway that could be associated with V1RE10 activity modulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, which could indirectly reduce V1RE10 activity by inhibiting related stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can suppress the JNK signaling, potentially diminishing the functional activity of V1RE10. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that can block the MAPK/ERK pathway, possibly leading to decreased activity of V1RE10. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor that could affect signaling cascades relevant to V1RE10 activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
A V-ATPase inhibitor, which could disrupt endosomal acidification and indirectly affect V1RE10 reliant signaling pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A broad-spectrum protein kinase C inhibitor that could modulate signaling pathways impacting V1RE10 function. | ||||||